BioCentury | Jan 25, 2016
Clinical News

MiR-103/107: Phase I started

...LSE:AZN; NYSE:AZN), London, U.K. Product: MiR-103/107 ( RG-125 , AZD4076 ) Business: Hepatic Molecular target: MicroRNA-103 (miR-103)...
BioCentury | Mar 10, 2014
Company News

Regulus, AstraZeneca deal

...Regulus disclosed in its 2013 earnings that it and partner AstraZeneca have selected microRNA-103 (miR-103) and miR-107...
BioCentury | Jun 16, 2011
Distillery Therapeutics

Indication: Endocrine disease therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Diabetes; obesity MicroRNA-103 (miR-103)...
Items per page:
1 - 3 of 3